Parkinson’s disease (PD) is a brain disorder that causes unintended or uncontrollable movements, such as shaking, stiffness, and difficulty with balance and coordination. Symptoms usually begin gradually and worsen over time. As the disease progresses, people may have difficulty walking and talking. According to a 2019 study the “risk of developing PD is twice as high in men than women, but women have a higher mortality rate and faster progression of the disease. Moreover, motor and nonmotor symptoms, response to treatments and disease risk factors differ between women and men.”
Newel Health, an Italy-based digital health company, has received a $2.7M grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance the research and development of Soturi, a Digital Therapeutic (DTx) solution for personalized medication and treatment plan optimization for people with Parkinson’s disease.
Gerry Chillè, Chief Strategy and Innovation Officer, Newel Health, explains: “The Soturi app seeks to improve the lives of people living with Parkinson’s disease (PD) using data collected from a wearable sensor to determine how people are being impacted by PD in a free-living context. Soturi’s proprietary algorithms analyze the collected data to determine optimal treatment plan specific to the individual. It is an honor to have The Michael J. Fox Foundation fund our team’s innovative approach and the potential benefits that our digital solution can deliver to the PD community.”